Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens

L. Repetto, S. Chiara, M. Pace, T. Guido, M. Bruzzone, C. Oliva, C. Murolo, P. F. Conte, R. Rosso

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Eight factors were analyzed for prognostic significance in univariate analyses in a series of 76 women with stage IV ovarian carcinoma treated with combination chemotherapies including cisplatin or carboplatin. The clinical objective and pathologic complete response rates were 51.2% and 27.3%, respectively. Median overall survival and progression-free survival were 15 and 7 months, respectively. No variables reached statistical significance. Trends toward better survival were noted for grades 1 and 2 for the adriamycin-containing regimen. Using progression-free survival as an end point, significant prognostic factors included complete clinical or pathologic response. Our data confirm that the standard approach is unlikely to modify the clinical outcome of stage IV ovarian cancer. New treatment modalities including high-dose-intensity regimens and neo-adjuvant chemotherapy delivered before surgery could improve clinical results. Moreover, biologic characterization of ovarian tumors may provide information to design specifically targeted treatment.

Original languageEnglish
Pages (from-to)274-277
Number of pages4
JournalTumori
Volume76
Issue number3
Publication statusPublished - 1990

Fingerprint

Platinum
Disease-Free Survival
Carcinoma
Survival
Carboplatin
Adjuvant Chemotherapy
Combination Drug Therapy
Ovarian Neoplasms
Doxorubicin
Cisplatin
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Cancer Research

Cite this

Repetto, L., Chiara, S., Pace, M., Guido, T., Bruzzone, M., Oliva, C., ... Rosso, R. (1990). Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens. Tumori, 76(3), 274-277.

Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens. / Repetto, L.; Chiara, S.; Pace, M.; Guido, T.; Bruzzone, M.; Oliva, C.; Murolo, C.; Conte, P. F.; Rosso, R.

In: Tumori, Vol. 76, No. 3, 1990, p. 274-277.

Research output: Contribution to journalArticle

Repetto, L, Chiara, S, Pace, M, Guido, T, Bruzzone, M, Oliva, C, Murolo, C, Conte, PF & Rosso, R 1990, 'Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens', Tumori, vol. 76, no. 3, pp. 274-277.
Repetto L, Chiara S, Pace M, Guido T, Bruzzone M, Oliva C et al. Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens. Tumori. 1990;76(3):274-277.
Repetto, L. ; Chiara, S. ; Pace, M. ; Guido, T. ; Bruzzone, M. ; Oliva, C. ; Murolo, C. ; Conte, P. F. ; Rosso, R. / Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens. In: Tumori. 1990 ; Vol. 76, No. 3. pp. 274-277.
@article{4410baff0d54467890000a63868a9118,
title = "Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens",
abstract = "Eight factors were analyzed for prognostic significance in univariate analyses in a series of 76 women with stage IV ovarian carcinoma treated with combination chemotherapies including cisplatin or carboplatin. The clinical objective and pathologic complete response rates were 51.2{\%} and 27.3{\%}, respectively. Median overall survival and progression-free survival were 15 and 7 months, respectively. No variables reached statistical significance. Trends toward better survival were noted for grades 1 and 2 for the adriamycin-containing regimen. Using progression-free survival as an end point, significant prognostic factors included complete clinical or pathologic response. Our data confirm that the standard approach is unlikely to modify the clinical outcome of stage IV ovarian cancer. New treatment modalities including high-dose-intensity regimens and neo-adjuvant chemotherapy delivered before surgery could improve clinical results. Moreover, biologic characterization of ovarian tumors may provide information to design specifically targeted treatment.",
author = "L. Repetto and S. Chiara and M. Pace and T. Guido and M. Bruzzone and C. Oliva and C. Murolo and Conte, {P. F.} and R. Rosso",
year = "1990",
language = "English",
volume = "76",
pages = "274--277",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Prognostic factors in stage IV ovarian carcinoma treated with platinum-based regimens

AU - Repetto, L.

AU - Chiara, S.

AU - Pace, M.

AU - Guido, T.

AU - Bruzzone, M.

AU - Oliva, C.

AU - Murolo, C.

AU - Conte, P. F.

AU - Rosso, R.

PY - 1990

Y1 - 1990

N2 - Eight factors were analyzed for prognostic significance in univariate analyses in a series of 76 women with stage IV ovarian carcinoma treated with combination chemotherapies including cisplatin or carboplatin. The clinical objective and pathologic complete response rates were 51.2% and 27.3%, respectively. Median overall survival and progression-free survival were 15 and 7 months, respectively. No variables reached statistical significance. Trends toward better survival were noted for grades 1 and 2 for the adriamycin-containing regimen. Using progression-free survival as an end point, significant prognostic factors included complete clinical or pathologic response. Our data confirm that the standard approach is unlikely to modify the clinical outcome of stage IV ovarian cancer. New treatment modalities including high-dose-intensity regimens and neo-adjuvant chemotherapy delivered before surgery could improve clinical results. Moreover, biologic characterization of ovarian tumors may provide information to design specifically targeted treatment.

AB - Eight factors were analyzed for prognostic significance in univariate analyses in a series of 76 women with stage IV ovarian carcinoma treated with combination chemotherapies including cisplatin or carboplatin. The clinical objective and pathologic complete response rates were 51.2% and 27.3%, respectively. Median overall survival and progression-free survival were 15 and 7 months, respectively. No variables reached statistical significance. Trends toward better survival were noted for grades 1 and 2 for the adriamycin-containing regimen. Using progression-free survival as an end point, significant prognostic factors included complete clinical or pathologic response. Our data confirm that the standard approach is unlikely to modify the clinical outcome of stage IV ovarian cancer. New treatment modalities including high-dose-intensity regimens and neo-adjuvant chemotherapy delivered before surgery could improve clinical results. Moreover, biologic characterization of ovarian tumors may provide information to design specifically targeted treatment.

UR - http://www.scopus.com/inward/record.url?scp=0025000686&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025000686&partnerID=8YFLogxK

M3 - Article

C2 - 2195729

AN - SCOPUS:0025000686

VL - 76

SP - 274

EP - 277

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 3

ER -